Handa Pharmaceuticals (ROCO:6620) Tariff Resilience Score: 0/10 (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
76 GF Score
Price NT$87.30
GF Value NT$183.83
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Handa Pharmaceuticals Tariff Resilience Score?

Handa Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

Handa Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Handa Pharmaceuticals might have .

Handa Pharmaceuticals  (ROCO:6620) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Handa Pharmaceuticals Tariff Resilience Score Related Terms

ROCO:6620
76GF Score
Handa Pharmaceuticals Inc ROCO:6620
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$87.30 is trading 52.5% below its estimated GF Value™ of NT$183.83. GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ROCO:6620:

  • Tariff Resilience Score: 0
  • GF Value™: NT$183.83 vs. price of NT$87.30 (52.5% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
76GF Score

Get the complete analysis for ROCO:6620

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$87.30
Price
NT$183.83
GF Value